Company intelligence
CROSSJECT
Le leader de l’auto-injection sans aiguille pour les situations d’urgences vitales
About CROSSJECT
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Verified activity
Signals from CROSSJECT
2 published signals
Presence & Recognition
CROSSJECT welcomed Océane Godard, a Côte-d’Or deputy, to present the company, teams, and development challenges.
Reported by CROSSJECT
Presence & Recognition
CROSSJECT welcomed Océane Godard, Member of the French National Assembly for Côte-d’Or, to the company premises to introduce her to activities, teams, and challenges in the development of CROSSJECT.
Reported by CROSSJECT